Retro Biosciences

Retro Biosciences is a Redwood City, California longevity biotechnology company founded in 2021 whose stated mission is to add ten years to healthy human lifespan. Its published preclinical pipeline spans RTR242, a small-molecule autophagy-flux booster aimed at Alzheimer's disease; RTR888, iPSC-derived microglial progenitors for CNS conditions; RTR890, iPSC-derived hematopoietic stem cells for blood disorders; AAV-delivered in vivo tissue reprogramming for osteoarthritis and age-related hearing loss; and AI-designed protein therapeutics, the last built on a 2025 collaboration with OpenAI on a protein-engineering model for reprogramming factors. Retro was seeded with $180M from Sam Altman and reported a $1.8B valuation in 2026. It is a therapeutics company rather than a software company: it operates a public GitHub organization of internal lab-automation and bioinformatics tooling, but publishes no API, SDK, developer portal or machine-readable contract of any kind.

Retro Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Longevity, and Aging.

Retro Biosciences’ developer surface includes engineering blog and 12 more developer resources.

🌐 Visit website 📡 Source on GitHub

7.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyLife SciencesLongevityAgingTherapeuticsCell TherapyGene TherapyDrug DiscoveryRegenerative MedicineNeuroscienceUnited States

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 7.0/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.6 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/retro-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 6

The organization behind the API

Website

About

Blog

Careers

LinkedIn

Twitter

Twitter

Other 3

Properties that don't map to a standard resource type

Product

Product

Team

Team

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: retro-biosciences
name: Retro Biosciences
description: 'Retro Biosciences is a Redwood City, California longevity biotechnology company founded in 2021 whose stated
  mission is to add ten years to healthy human lifespan. Its published preclinical pipeline spans RTR242, a small-molecule
  autophagy-flux booster aimed at Alzheimer''s disease; RTR888, iPSC-derived microglial progenitors for CNS conditions; RTR890,
  iPSC-derived hematopoietic stem cells for blood disorders; AAV-delivered in vivo tissue reprogramming for osteoarthritis
  and age-related hearing loss; and AI-designed protein therapeutics, the last built on a 2025 collaboration with OpenAI on
  a protein-engineering model for reprogramming factors. Retro was seeded with $180M from Sam Altman and reported a $1.8B
  valuation in 2026. It is a therapeutics company rather than a software company: it operates a public GitHub organization
  of internal lab-automation and bioinformatics tooling, but publishes no API, SDK, developer portal or machine-readable contract
  of any kind.'
image: https://www.retro.bio/opengraph-image.jpg
url: https://raw.githubusercontent.com/api-evangelist/retro-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biotechnology
- Life Sciences
- Longevity
- Aging
- Therapeutics
- Cell Therapy
- Gene Therapy
- Drug Discovery
- Regenerative Medicine
- Neuroscience
- United States
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/retro-biosciences-domain-security.yml
- type: LLMsTxt
  url: llms/retro-biosciences-llms.txt
- type: Website
  url: https://www.retro.bio/
- type: About
  url: https://www.retro.bio/science
- type: Product
  url: https://www.retro.bio/pipeline
- type: Team
  url: https://www.retro.bio/team
- type: Blog
  url: https://www.retro.bio/blog
- type: Careers
  url: https://www.retro.bio/careers
- type: Contact
  url: mailto:hi@retro.bio
- type: GitHubOrganization
  url: https://github.com/retrobiosciences
- type: LinkedIn
  url: https://www.linkedin.com/company/retro-biosciences
- type: Twitter
  url: https://twitter.com/RetroBio_
- type: SecondaryMarket
  url: https://www.hiive.com/securities/retro-biosciences-stock
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Retro Biosciences is a preclinical therapeutics developer whose products are drugs, not software; its entire published
    site is the seven URLs in its own sitemap.xml (home, science, pipeline, team, careers, blog, one post), and api., developer.
    and docs.retro.bio are Vercel wildcard records that answer DEPLOYMENT_NOT_FOUND rather than serving anything.
  evidence:
  - url: https://www.retro.bio/sitemap.xml
    status: 200
  - url: https://www.retro.bio/openapi.json
    status: 404
  - url: https://www.retro.bio/.well-known/agent-card.json
    status: 404
  - url: https://www.retro.bio/.well-known/security.txt
    status: 404
  - url: https://api.retro.bio/openapi.json
    status: 404
  - url: https://developer.retro.bio/
    status: 404
  - url: https://docs.retro.bio/
    status: 404
  - url: https://www.retro.bio/llms.txt
    status: 404
  checked: '2026-08-05'